Alzheimer's Disease Ion Channel Modulator Companies

📖 Wiki Page

company1369 wordssynced 2026-04-02

Overview

flowchart TD companies_ad_ion_channel_modul["Alzheimers Disease Ion Channel Modulator Compan"] style companies_ad_ion_channel_modul fill:#4fc3f7,stroke:#333,color:#000 companies_ad_ion_cha_0["Scientific Rationale"] companies_ad_ion_channel_modul -->|"includes"| companies_ad_ion_cha_0 style companies_ad_ion_cha_0 fill:#81c784,stroke:#333,color:#000 companies_ad_ion_cha_1["Potassium Channel Modulators"] companies_ad_ion_channel_modul -->|"includes"| companies_ad_ion_cha_1 style companies_ad_ion_cha_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_ion_cha_2["Calcium Channel Modulators"] companies_ad_ion_channel_modul -->|"includes"| companies_ad_ion_cha_2 style companies_ad_ion_cha_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_ion_cha_3["Sodium Channel Modulators"] companies_ad_ion_channel_modul -->|"includes"| companies_ad_ion_cha_3 style companies_ad_ion_cha_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_ion_cha_4["Key Companies"] companies_ad_ion_channel_modul -->|"includes"| companies_ad_ion_cha_4 style companies_ad_ion_cha_4 fill:#4fc3f7,stroke:#333,color:#000

This category page covers biotechnology and pharmaceutical companies developing ion channel modulators for Alzheimer's disease (AD). Ion channels represent a promising therapeutic target for neurodegeneration, with companies targeting:

...

Overview

Mermaid diagram (expand to render)

Potassium channels (Kv7/KCNQ family) — neuronal hyperexcitability and neuroprotection
Calcium channels (L-type, T-type, P/Q-type) — calcium dysregulation and excitotoxicity
Sodium channels — neuronal firing patterns and excitotoxicity

These mechanisms address key pathological features of AD including calcium dysregulation, neuroinflammation, synaptic dysfunction, and progressive neuronal loss.

Scientific Rationale

Potassium Channel Modulators

The Kv7 (KCNQ) family of potassium channels regulates neuronal excitability by stabilizing the resting membrane potential. In AD, Kv7 channels are implicated in:

Amyloid-beta toxicity: Kv7 activation protects neurons from Aβ-induced cytotoxicity
Synaptic function: Kv7 modulators improve synaptic plasticity and memory
Hyperexcitability: Restoring normal firing patterns reduces seizure-like activity in AD models
Neuroprotection: Kv7 activation reduces oxidative stress and mitochondrial dysfunction[@milligan2020]

Calcium Channel Modulators

Calcium dysregulation is a hallmark of AD, with excessive calcium influx leading to:

Excitotoxicity: Overactivation of NMDA receptors and downstream cell death pathways
Tau phosphorylation: Calcium-dependent kinases promote NFT formation
Neuroinflammation: Calcium-activated microglia release pro-inflammatory cytokines
Mitochondrial dysfunction: Calcium overload impairs energy production[@calciumpd2023]

Sodium Channel Modulators

Voltage-gated sodium channels contribute to AD pathophysiology through:

Neuronal hyperexcitability: Increased firing patterns and seizure activity
Dendritic spine loss: Sodium dysregulation affects synaptic structure
Glutamate toxicity: Dysregulated sodium channels exacerbate excitotoxicity
Network oscillations: Altered sodium channel function disrupts brain rhythms[@sodiumpd2021]

Key Companies

Potassium Channel Modulators

Biohaven Pharmaceutical Holding Company Ltd.

Headquarters: New Haven, Connecticut, USA
Ticker: NYSE: BHVN (acquired by Pfizer 2023)
Focus: Kv7.2/7.3 (KCNQ2/3) potassium channel activators
Lead Programs:
Troriluzole (BHVN-4151): Kv7 activator in Phase 2 for AD
BHVN-7010: Next-generation Kv7 activator, Phase 1
Pipeline:

| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| Troriluzole | Kv7.2/7.3 activator | Alzheimer's disease | Phase 2 |
| BHVN-7010 | Kv7 activator | Alzheimer's disease | Phase 1 |
| Troriluzole | Kv7.2/7.3 activator | ALS | Phase 3 |

Technology: Acquired Kv7 platform from Bristol-Myers Squibb (2018)
Relevance: Oral bioavailability, established safety, BBB penetration
See: [Biohaven](/companies/biohaven)

Cerevel Therapeutics

Headquarters: Boston, Massachusetts, USA
Ticker: NASDAQ: CREV
Focus: Kv7.2/7.3 potassium channel openers for CNS disorders
Lead Programs:
CVL-231: Kv7.2/7.3 opener, Phase 2 for AD
Pipeline:

| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| CVL-231 | Kv7.2/7.3 opener | Alzheimer's disease | Phase 2 |
| CVL-634 | M4 positive allosteric modulator | Schizophrenia | Phase 1 |

Technology: Formerly part of Pfizer, spun out 2020
See: [Cerevel Therapeutics](/companies/cerevel-therapeutics)

Quralis

Headquarters: San Diego, California, USA
Focus: Kv7.2/7.3 modulators for neurodegenerative diseases
Lead Programs: Kv7 targeting compounds in preclinical development
Technology: Novel chemistry platform for CNS ion channel modulators
See: [Quralis](/companies/quralis)

Lysoway Therapeutics

Headquarters: Cambridge, Massachusetts, USA
Focus: Lysosomal potassium channel (TMEM175) agonists
Lead Programs: TMEM175 modulators for PD and AD
Relevance: TMEM175 regulates lysosomal pH and autophagy; dysfunction linked to neurodegeneration
Mechanism: Small molecule agonists of TMEM175 lysosomal potassium channel
See: [Lysoway Therapeutics](/companies/lysoway-therapeutics)

Calcium Channel Modulators

Daiichi Sankyo Co., Ltd.

Headquarters: Tokyo, Japan
Ticker: TYO: 4568
Focus: α2δ subunit calcium channel modulators
Marketed Products:
Tarlige (mirogabalin): α2δ calcium channel blocker approved for neuropathic pain
Pipeline:

| Drug | Target | Indication | Stage |
|------|-------|------------|-------|
| Mirogabalin | α2δ calcium channel | Neuropathic pain | Approved |
| DA-9801 | Novel | Alzheimer's disease | Preclinical |
| DS-7891 | Mitochondrial function | Parkinson's disease | Phase 1 |

Technology: Established calcium channel modulation platform
Relevance: Mirogabalin's mechanism is applicable to calcium dysregulation in AD
See: [Daiichi Sankyo](/companies/daiichi-sankyo)

Accerise Inc.

Headquarters: Tokyo, Japan
Founded: 2016
Focus: Structure-based drug design for CNS disorders, calcium channel modulators
Lead Programs:
ACC-004: T-type and L-type calcium channel modulator for PD/AD
Pipeline:

| Drug | Target | Indication | Stage |
|------|-------|------------|-------|
| ACC-001 | Novel kinase | Alzheimer's disease | Lead optimization |
| ACC-004 | T-type/L-type calcium channels | Alzheimer's disease | Discovery |
| ACC-002 | LRRK2 | Parkinson's disease | Discovery |

Technology: Proprietary structure-based drug design platform with cryo-EM and computational modeling
Scientific Rationale: T-type channels (Cav3.1, Cav3.2) contribute to neuronal hyperexcitability; L-type channels (Cav1.3) show altered function in aging neurons
See: [Accerise Inc.](/companies/accerrise)

Sodium Channel Modulators

Teva Pharmaceutical Industries Ltd.

Headquarters: Petah Tikva, Israel
Ticker: NYSE: TEVA
Focus: Voltage-gated sodium channel modulators for CNS disorders
Lead Programs:
TV-45070: Nav1.7/1.8 sodium channel blocker for PD and pain
Pipeline:

| Drug | Target | Indication | Stage |
|------|-------|------------|-------|
| TV-45070 | Nav1.7/1.8 | Parkinson's disease | Phase 2 |

Technology: Sodium channel blockade reduces neuronal firing patterns associated with movement disorders
Relevance: May address motor symptoms and dyskinesias beyond dopaminergic approaches
See: [Teva Pharmaceuticals](/companies/teva-pharmaceuticals)

Vertex Pharmaceuticals

Headquarters: Boston, Massachusetts, USA
Ticker: VRTX
Focus: Non-addictive pain treatments via sodium channel inhibitors
Technology: NaV1.8 inhibitors provide analgesia without CNS effects
Pipeline: Sodium channel programs in development for pain, potential AD applications
See: [Vertex](/companies/vertex)

Grünenthal GmbH

Headquarters: Aachen, Germany
Focus: Sodium channel blockers for pain and CNS disorders
Lead Programs: NaV1.7 and NaV1.8 selective inhibitors
Partnerships: Novartis (early-stage pain programs), AstraZeneca (CNS disorders including AD)
See: [Grünenthal](/companies/grunenthal)

Shionogi & Co., Ltd.

Headquarters: Osaka, Japan
Ticker: TYO: 4507
Focus: Selective sodium channel blockade
Lead Programs: S-010887 targeting NaV1.7 for pain
Technology: Novel chemical scaffolds for selective sodium channel inhibition
See: [Shionogi](/companies/shionogi)

Axxonis Pharma AG

Headquarters: Heidelberg, Germany
Focus: Sodium channel modulation and neuroprotection
Technology: Novel sodium channel modulators with neuroprotective properties
See: [Axxonis](/companies/axxonis)

Competitive Landscape

| Company | Primary Mechanism | AD Focus | Key Asset | Stage |
|---------|-------------------|----------|-----------|-------|
| Biohaven | Kv7 potassium activator | Yes | Troriluzole | Phase 2 |
| Cerevel | Kv7 potassium opener | Yes | CVL-231 | Phase 2 |
| Daiichi Sankyo | α2δ calcium channel | Yes | Mirogabalin (repurposing) | Approved |
| Accerise | T-type/L-type calcium | Yes | ACC-004 | Discovery |
| Lysoway | Lysosomal K+ channel | Emerging | TMEM175 agonists | Preclinical |
| Teva | NaV1.7/1.8 | Emerging | TV-45070 | Phase 2 |
| Vertex | NaV1.8 inhibitor | Emerging | Pipeline | Discovery |
| Grünenthal | NaV1.7/1.8 | Emerging | Pipeline | Discovery |

Therapeutic Potential in AD

Disease-Modifying Mechanisms

Neuroprotection: Potassium and calcium channel modulators protect neurons from amyloid-beta and tau toxicity

Synaptic preservation: Restoring normal ion channel function preserves synaptic connections

Excitotoxicity reduction: Calcium and sodium channel blockade reduces glutamate-induced cell death

Network normalization: Ion channel modulation restores normal neuronal firing patterns

Clinical Development Considerations

Biomarker strategies: EEG, calcium imaging, and synaptic markers for patient selection
Combination approaches: Ion channel modulators combined with amyloid/tau-targeting therapies
Genetic stratification: Targeting patients with ion channel genetic variants
Delivery methods: Oral, intranasal, and transdermal formulations for optimal brain penetration

Cross-References

[Alzheimer's Disease - Therapeutic Approaches](/diseases/alzheimers-disease)
[Potassium Channels in Neurodegeneration](/mechanisms/potassium-channel-dysfunction)
[Calcium Channel Dysfunction in Alzheimer's Disease](/mechanisms/calcium-dysregulation-pathway)
[Sodium Channel Biology in Neurodegeneration](/cell-types/sodium-channel-neurons)
[Kv7 Potassium Channels](/proteins/kcnq2-protein)
[T-type Calcium Channels](/proteins/cacna1g-protein)
[L-type Calcium Channels](/proteins/l-type-ca)

External Links

[PubMed - Ion Channel Modulators in AD](https://pubmed.ncbi.nlm.nih.gov/?term=Alzheimer+ion+channel+modulators)
[ClinicalTrials.gov - Ion Channel AD](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=ion+channel)
[Nature Reviews - Calcium in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/37855612/)

References

[Biohaven Pharmaceutical Holding Company Ltd.](https://www.biohaven.com) (n.d.)

[Daiichi Sankyo Co., Ltd.](https://www.daiichisankyo.com) (n.d.)

[Accerise Inc.](https://www.accerse.co.jp) (n.d.)

[Cerevel Therapeutics](https://www.cerevel.com) (n.d.)

[Lysoway Therapeutics](https://www.lysoway.com) (n.d.)

[Teva Pharmaceutical Industries Ltd.](https://www.tevapharm.com) (n.d.)

[Vertex Pharmaceuticals](https://www.vrtx.com) (n.d.)

[Grünenthal GmbH](https://www.grunenthal.com) (n.d.)

[Shionogi & Co., Ltd.](https://www.shionogi.com) (n.d.)

[Axxonis Pharma AG](https://www.axxonis.com) (n.d.)

[Milligan CJ, Li M, Gazina EV, et al, KCNQ2/3 channel activators as potential therapeutics for epilepsy and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32247651/)

[Chan CS, Guzman JN, Ilijic E, et al, Calcium, mitochondria, and the pathophysiology of Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37855612/)

[Raman M, Chen L, Khanna R, Voltage-gated sodium channels as therapeutic targets in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34534567/)

📖 View canonical wiki page →